Session Date & Time:
Poster No. 308: Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria
Data included in the abstract are through
- Data through 24 weeks for Cohorts 1-3 (0.5, 1.5 and 3.0 mg/kg doses)
- Data through 20 weeks for Cohort 4 (4.5 mg/kg dose); 6 of 9 patients available at this timepoint as of the data cut-off date
Webcast and Conference Call
The Company will host a webcast presentation of the data on
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.
Senior Vice President, Corporate Affairs & Administration
Source: Celldex Therapeutics, Inc.